Aprepitant Effects in Intravenous Heroin Dependence

Status Completed

Clinical Trial Summary

Current treatments for opioid addiction would benefit by the addition of a non-opioid based treatment medication. Recent behavioral studies have shown that the neurokinin-1 (NK1) receptor is involved in opioid reward and withdrawal. This study proposes to study a potential non-opioid treatment, the clinically available, FDA approved, NK1 antagonist aprepitant, in opioid addicted patients. Based on the unique behavioral and pharmacological characteristics of opioid addiction, and what is known of the currently employed treatments, the investigators propose that the therapeutic mechanism of any potential opioid addiction treatment medication must include the ability to reduce opioid withdrawal. This is of particular importance during treatment initiation (eg. detoxification). In addition, for long-term treatment and relapse prevention, it is important to manage drug craving and inhibit the rewarding effects of opioids if patients do experience a slip. Therefore, the investigators propose to study aprepitant using human models of opioid withdrawal, craving and acute opioid reward and reinforcement. The investigators will also include a neuro-economics choice procedure paradigm.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01527994
Study type	Interventional
Source	NYU Langone Health
Contact
Status	Completed
Phase	Phase 1
Start date	January 2012
Completion date	February 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03675386` - Reducing Opioid Use for Chronic Pain Patients Following Surgery	N/A
Completed	`NCT02593474` - Medication-Assisted Treatment for Youth With Substance Use Disorders	Phase 1
Completed	`NCT02294253` - Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone	Phase 2/Phase 3
Completed	`NCT02282306` - Phone Interview to Prevent Recurring Opioid Overdoses	N/A
Completed	`NCT01592461` - Starting Treatment With Agonist Replacement Therapies Follow-up Study	N/A
Terminated	`NCT00768482` - A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence	Phase 3
Completed	`NCT01741350` - Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users	N/A
Terminated	`NCT04121546` - Collaborative Care for Opioid Dependence And Pain Pilot Study	N/A
Withdrawn	`NCT03368794` - Naloxone to TReatment Entry in the Emergency Setting	N/A
Completed	`NCT03447743` - Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder	Early Phase 1
Completed	`NCT04464421` - SMART Effectiveness Trial	N/A
Recruiting	`NCT04189523` - Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage	N/A
Completed	`NCT03305666` - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures	Phase 4
Recruiting	`NCT04003948` - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification	Phase 2
Not yet recruiting	`NCT03813095` - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction	Phase 2
Terminated	`NCT02935101` - Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants	Phase 2
Completed	`NCT01895270` - Improving Buprenorphine Detoxification Outcomes With Isradipine	Phase 1/Phase 2
Completed	`NCT01717963` - Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway	Phase 3
Completed	`NCT01425060` - Improving Effective Contraceptive Use Among Opioid-maintained Women	Phase 1
Completed	`NCT02324725` - Biomarkers of Injectable Extended Release Naltrexone Treatment	Phase 4